**Abstract**

**Background**: This post-hoc analysis was performed to compare the overall incidence, time-to-onset (TTO) and time-to-resolution (TTR) of extrapyramidal symptoms (EPS)-related adverse events (AEs) after treatment with paliperidone palmitate (PP) 3-monthly (PP3M) vs. 1-monthly (PP1M) long-acting injectable in patients with schizophrenia.

**Methods:** EPS-related AEs were summarized by grouped terms (Overall and further classified into Dystonia, Dyskinesia, Hyperkinesia, Parkinsonism and Tremor), study phases (open-label \[OL\]: PP1M, double-blind \[DB\]: PP1M or PP3M), TTO and TTR, and descriptively compared. TTO and TTR were further analyzed by final OL dose (50/75 mg eq., 100 mg eq. and 150 mg eq.) and age (18--25, 26--50 and 50+ years) subgroups.

**Results:** Overall incidence of EPS-related AEs was 12.6% (PP1M) during OL phase, reducing to 8.3% (PP3M) and 7.4% (PP1M) during DB phase. Median TTO for all EPS-related AEs was 17 days (range: 1--120) after PP1M OL treatment; 115 days (range: 1--323) and 98.5 days (range: 1--322) after treatment with PP3M and PP1M, respectively (DB phase). Median TTR was 36.5 days (range: 1--127) in PP1M group (OL), and was generally similar for PP3M (91 days \[range: 1--336\]) vs. PP1M (85.5 days \[range: 1--337\]) during DB phase. Overall median TTO and TTR values were comparable between PP3M and PP1M formulations. Subgroup analysis revealed no clear dose-response or age-related differences in TTO and TTR of EPS-events for the two formulations.

**Discussion:** The overall incidence of EPS-related AEs, TTO and TTR of EPS-events were found to be comparable in patients with schizophrenia receiving either PP3M or PP1M long-acting injectable.
